A combination immunotherapy for the patients with advanced or metastatic solid cancer
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2018
At a glance
- Drugs CYT 001 (Primary) ; Eftilagimod alpha (Primary) ; Poly ICLC (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Proof of concept
- 17 Apr 2018 New trial record
- 16 Mar 2018 Interim results were presented at ASCO2017 (June 2017), as reported in a CYTLIMIC media release.
- 16 Mar 2018 According to a CYTLIMIC media release, Shoichi Hazama is Co-Investigator of this trial. Based on the data from this trial, the company has started YCP02 study.